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Abstract: Pitavastatin is a potent HMG-CoA reductase inhibitor and efficient hepatocyte 
low-density lipoprotein cholesterol (LDL-C) receptor inducer, producing robust reduction of 
the serum LDL-C levels, even at a low dose. Pitavastatin and its lactone form are minimally 
metabolized by CYP enzymes, and are therefore associated with minimal drug–drug interac-
tions (DDIs). Pitavastatin 2 to 4 mg has potent LDL-C-reducing activity, equivalent to that of 
atorvastatin 10 to 20 mg; several clinical trials have revealed consistently superior high-density 
lipoprotein cholesterol (HDL-C) elevating activity of pitavastatin than that of atorvastatin. 
Pitavastatin-induced HDL-C elevation has been shown to be sustained, even incremental, in 
long-term clinical trials. Pitavastatin was as well-tolerated as atorvastatin or simvastatin in double-
blind randomized clinical trials. Two-year long-term safety and effectiveness of pitavastain has 
been confirmed in a large-scale, prospective post-marketing surveillance. The safety and efficacy 
profile of pitavastatin is favorable for the treatment of dyslipidemia, especially in metabolic 
syndrome patients. In addition to control of LDL-C, adequate control of triglyceride (TG) and 
HDL-C, hypertension and hyperglycemia is also necessary in metabolic syndrome patients. 
Pitavastatin produces adequate control of LDL-C and TG, along with potent and incremental 
HDL-C elevation, with a low frequency of DDIs.
Keywords: HMG-CoA reductase inhibitor, pitavastatin, efficacy, safety, drug–drug 
interaction
Introduction
Low-density lipoprotein cholesterol (LDL-C) is an established risk factor for 
atherosclerotic disease, especially coronary artery disease (CAD), therefore, 
management of serum LDL-C levels is evidently the most important goal in the treatment 
of dyslipidemia.1–3 Several large-scale studies on primary and secondary prevention of 
coronary heart disease (CHD) conducted using 3-hydroxy-3-methylglutaryl coenzyme 
A (HMG-CoA) reductase inhibitors (statins) have reported that the LDL-C-lowering 
statin therapy markedly reduced the incidence of CAD.4 These results provide the 
rationale for wider use of statins in CHD treatment. A recent meta-analysis of 
10 representative trials reported that treatment with statins for primary prevention 
reduced the risk of major coronary events by 30%, and that the treatment effect 
was noted even in clinical subgroups for which inconsistent results on efficacy have 
been reported, including older people, women, and patients with diabetes mellitus.5 
While the statins have been proven to be definitely efficacious in CHD prevention, 
the percentage of patients in whom the LDL-C treatment goal recommended in the 
National Cholesterol Education Program (NCEP)-Adult Treatment Panel (ATP) III Vascular Health and Risk Management 2009:5 922
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in the US in 2003 is achieved by statin therapy alone is 
unsatisfactory: 55% in patients with diabetes mellitus, 40% 
in those with other CAD risk equivalents, and 62% in those 
with CHD.6 Similarly, the rate of achievement by risk category 
of the LDL-C treatment goals as reported in the 2002 report 
of the Japan Atherosclerosis Society guidelines in 2003, 
is also unsatisfactory: 51% in patients with category B3, 
54% in those with B4, and 31% in those with C.7 Therefore, 
although strong statins such as atorvastatin, pitavastatin, and 
rosuvastatin are available for the treatment of dyslipidemia in 
routine clinical practice, use of these drugs at conventional 
doses may be unsatisfactory for LDL-C management in 
patients, including those with diabetes mellitus, other CHD 
risk equivalents, and CHD. For such patients, administration 
of statins at high doses or concomitant use of other agents for 
dyslipidemia should be considered. However, administration 
of statins at high doses may increase the risk of serious 
adverse drug reactions such as rhabdomyolysis. In addition, 
since concomitant therapy with a statin and ezemitibe 
has not provided sufficient evidence of the prevention 
of cardiovascular events, combined administration of 
lipid-lowering drugs has not been established for LDL-C 
management. From the above, combined therapy based on 
statins with other drugs, including those under development, 
is expected to be established.
Since even in patients with adequate reduction of the 
serum LDL-C levels, development of atherosclerotic disease, 
especially CAD, is not fully prevented, risk factors other than 
LDL-C should also be considered.8,9 For example, in the 
INTERHEART Study conducted on approximately 30000 
patients in 52 countries, the association of various risk fac-
tors with the onset of acute myocardial infarction (AMI) was 
determined. This study reported the 9 important risk factors 
of smoking, abnormal lipid balance (apolipoprotein [Apo] 
B/ApoA1 ratio), hypertension, diabetes, abdominal obesity, 
stress, decreased consumption of fruits and vegetables, 
alcohol intake, and decreased physical activity. Judging 
from the odds ratio, the impact of these risk factors were 
equivalent in men and women and also in all regions of the 
world.10 Because patients with these risk factors commonly 
have dyslipidemia, that is, hypertriglyceridemia and hypo-
HDL cholestrolemia, management of serum triglyceride 
(TG) and high-density lipoprotein cholesterol (HDL-C) 
levels may also be as important as that of LDL-C for the 
prevention of atherosclerotic disease. Therefore, treatment 
of dyslipidemia requires management of the serum TG and 
HDL-C levels as well, as also of the complications of hyper-
tension and diabetes, in addition to control of serum LDL-C 
levels, thus, combination therapy with a statin and other 
agents for dyslipidemia, hypertension, and diabetes should 
be considered. In particular, one of the recent major health 
issues emerging in developed countries is the metabolic 
syndrome, which has multiple risk factors other than LDL-C, 
and serves as a high risk factor for CHD. Patients with 
metabolic syndrome show high serum TG and low serum 
HDL-C levels, while the serum LDL-C levels may not be 
markedly elevated. Accordingly, statin monotherapy may 
not be efficient for comprehensive management of the lipid 
profile in these patients and concomitant therapy with other 
drugs for dyslipidemia, including fibrates and niacins, and 
cholesteryl ester transfer protein (CETP) inhibitors, which 
are under development, may be indicated. However, since 
concurrent therapy with statins and fibrates has been 
reported to be associated with an elevated risk of occurrence 
of rhabdomyolysis,11 attention must be paid to drug–drug 
interactions when combined therapy with a statin and other 
drugs is considered. In addition, management of not only 
lipid parameters, but also of the blood pressure and glucose 
levels is important in patients with metabolic syndrome, and 
concurrent treatment of antihypertensive and antidiabetic 
drugs may be necessary. Nonetheless, there is little evidence 
regarding the efficacy of combination therapy with existing 
drugs for dyslipidemia, hypertension, and hyperglycemia and 
drugs under development. Results of further clinical studies 
on these issues are expected.
Taken together, for ideal dyslipidemia treatment, 
management of the serum TG, HDL-C levels and of compli-
cations such as hypertension and diabetes is also important in 
addition to strict LDL-C management. To achieve this goal 
satisfactorily, therapy based on conventional doses of statins 
with a minimum risk of drug interactions is required.
Pharmacological actions  
and mechanism of actions  
of pitavastatin
Pitavastatin has a characteristic structure, with heptenoate as 
the basic structure and a quinoline ring at the core. Its side 
chain has fluorophenyl and cyclopropyl moieties (Figure 1). 
Its structure provides improved pharmacokinetics, including 
optimal activity as a HMG-CoA reductase inhibitor and better 
drug absorption. Figure 2 shows simulation imaging of the 
binding mode with the active site (spliced out 5Å from the 
active center) on the reductase.12
In one study, the IC50 of pitavastatin for HMG-CoA 
reductase inhibition in rat liver microsomes was 6.8 nM, being 
2.4-fold higher than that of simvastatin and 6.8-fold higher Vascular Health and Risk Management 2009:5 923
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than that of pravastatin.13 Pitavastatin inhibits HMG-CoA 
reductase and synthesis of cholesterol in the liver like other 
statins, however, the IC50 for the inhibition of cholesterol 
synthesis from [14C] acetic acid in the cultured human 
hepatoma cell line HepG2 was found to be 5.8 nM, being 
2.9-fold higher than that of simvastatin and 5.7-fold higher 
than that of atorvastatin.14 Since these results might simply 
indicate stronger inhibition of HMG-CoA reductase by 
pitavastatin, the effects of the drugs on induction of the LDL 
receptor was compared at the standardized concentration 
determined by the inhibitory action of the drugs on cholesterol 
synthesis. Pitavastatin showed more effective induction of LDL 
receptor expression than either atorvastatin or simvastatin.14 
Pitavastatin induced expression of the LDL receptor more 
efficiently than the other statins and promoted the uptake of 
LDL from the blood to the liver to lower the serum LDL-C 
levels. The ED50 of oral pitavastatin for inhibition of sterol 
synthesis in the rat liver was 0.13 mg/kg, being 2.8-fold13 
and 15.9-fold higher, respectively, than that of simvastatin in 
rats and guinea pigs. This result showed pitavastatin inhibited 
the secretion of VLDL, one of the TG-rich lipoproteins, 
from the liver.15 In addition, the effect on the secretion of 
ApoA1, a constituent of HDL, from the liver was evaluated 
using HepG2 cells. Pitavastatin was noted to have superior 
ApoA1 secretion-promoting effect as compared to atorvastatin 
and simvastatin. Pitavastatin was also found to promote 
ATP-binding cassette transporter A1 (ABCA1) expression in 
HepG2 cells, and to possibly facilitate HDL neogenesis by 
ApoA1-dependent cholesterol efflux in hepatocytes.16
Pleiotropic effects of pitavastatin
Plaque rupture, the essential pathogenetic mechanism in 
acute coronary syndrome (ACS), is thought to be caused 
CO2–
F
N
2
Ca2+
HO
OH
Figure 1 Chemical structure of pitavastatin.
Figure 2 Binding image of pitavastatin and HMG-CoA reductase.12Vascular Health and Risk Management 2009:5 924
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by structural changes, including thinning of the fibrous cap 
or increased lipid core, and provocation of a certain type 
of inflammation.17 In general, statins have multifaceted 
effects called pleiotropic effects in addition to their 
LDL-C-lowering effect.18 Table 1 shows the pleiotropic 
effects of pitavastatin.
After administration of pitavastatin (0.5 mg/kg/day) 
in drinking water to Watanabe heritable hyperlipidemic 
(WHHL) rabbits for 16 weeks, the aortic arch of the 
animals was examined pathologically. Pitavastatin showed a 
tendency to improve the composition of vulnerable plaques, 
represented by increased collagen deposition and decreased 
macrophage infiltration (Table 2).19 Imaging analysis of the 
aorta revealed that the area occupied by collagen and the 
α-actin-positive area increased by about 66% and 92%, 
respectively, in the pitavastatin group; on the other hand, 
the macrophage-positive area was reduced by about 39%.19 
Thus, pitavastatin may improve the composition of vulnerable 
plaques and help plaque stabilization.
Additionally, in vitro experiments have shown that 
pitavastatin has an inhibitory effect on the C-reactive-protein-
induced interleukin-8 (IL-8) production by endothelial cells, 
and also on monocyte adhesion to the endothelial cells, via 
monocyte chemoattractant protein-1 (MCP-1) stimulation,20,21 
confirming the anti-inflammatory effects of the drug. 
Moreover, pitavastatin is reported to have an inhibitory 
effect on plasminogen activator inihibitor-1 (PAI-1)22,23 and 
tissue factor (TF)23 which are important factors in thrombosis 
Table 2 effect of pitavastatin on components of aortic plaque in wHHL rabits
Plaque components Control Pitavastatin Percent difference
α-SMA in the intima
  intimal area (mm2) 8.47 ± 0.64 4.54 ± 0.62** −46.4%
  α-SMA positive area (mm2) 0.68 ± 0.05 0.69 ± 0.08 +1.5%
  Percent area (%) 8.45 ± 0.52 16.2 ± 0.94** +91.7%
Collagen in the intima
  intimal area (mm2) 9.54 ± 0.69 5.78 ± 0.88** −39.4%
  Collagen positive area (mm2) 1.19 ± 0.15 1.28 ± 0.25 +7.6%
  Percent area (%) 12.2 ± 1.2 20.3 ± 1.6** +66.4%
Macrophage in the intima
  intimal area (mm2) 9.13 ± 0.66 5.27 ± 0.79** −42.3%
  Macrophage positive area (mm2) 2.95 ± 0.18 1.00 ± 0.16** −66.1%
  Percent area (%) 33.5 ± 2.1 20.3 ± 2.5** −39.4%
Notes: N = 11. Mean ± Se. **P  0.01 versus the control group.
Abbreviation: α-SMA, α-smooth muscle actin.
Modified from Suzuki et al.19
Table 1 Pleiotropic effects reported for pitavastatin
endothelial function eNOS mRNA expression↑, eT-1 mRNA expression↓22
Monocyte activation/endothelium-adhesion/migration Monocyte adhesion on endothelium↓,21 MCP-1 mRNA expression↓,22 iL-8 
production/mRNA expression↓,20,22 NF-κB transactivation↓,28 iCAM-1 mRNA 
expression↓29
Foam cell formation/cholesterol accumulation SMC proliferation↓,25,30 SMC migration↓,30 CD36 mRNA/protein expression↓,31 
Cholesterol accumulation in macrophage↓, apoB48R expression↓32
Plaque stabilization Accumulation of macrophages↓, collagen↑, MMPs↓19
Thrombosis formation TF mRNA/protein expression↓,23 PAi-1 mRNA expression/antigen secretion/
activity↓,22,23 t-PA mRNA expression/antigen secretion↑,23 TM mRNA expression/
cellular antigen/transcription rate↑22,24
Inflammatory markers CRP↓,33 PTX3 mRNA expression↓22,26
Anti-oxidation ROS production↓,34 PON1 promoter activity↑35
Notes: ↑, enhance or increase; ↓, suppress or decrease
Abbreviations: eNOS, endothelial nitric oxide synthase; eT-1, endothelin 1; MCP-1, monocyte chemoattractant protein 1; iL-8, interleukin 8; NF-κB, nuclear factor kappa B; 
iCAM-1, intercellular adhesion molecule 1; SMC, smooth muscle cell; MMPs, matrix metalloproteinases;   TF, tissue factor; PAi-1, plasminogen activator inhibitor 1; t-PA, tissue 
plasminogen activator;   TM, thrombomodulin; CRP, C-reactive protein; PTX3, pentraxin 3; ROS, reactive oxygen species; PON1, paraoxonase 1.Vascular Health and Risk Management 2009:5 925
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formation, and to induce tissue plasminogen activator (t-PA)23 
and thrombomodulin (TM) expression.22,24 Therefore, pitavas-
tatin is expected to exert its anti-atherosclerotic effect via 
various mechanisms.
These pleiotropic effects of pitavastatin were compared 
with those of other statins using the inhibitory effects on 
the proliferation of smooth muscle cells (SMCs) derived 
from the human coronary arteries as an indicator. Even at 
low concentrations, pitavastatin was found to inhibit the 
proliferation of SMCs derived from human coronary arteries 
more strongly than atorvastatin, simvastatin, fluvastatin, 
rosuvastatin, or pravastatin.25
To evaluate a new effect of pitavastatin on the blood 
vessels, the changes in the gene expression profiles brought 
about by statins were investigated in cultured normal human 
umbilical vein endothelial cells and normal human coronary 
artery SMCs by DNA microarray analysis. Pitavastatin 
inhibited the expression of pentraxin 3 (PTX3) related to 
acute inflammation.26 PTX3 is found to be elevated especially 
in arterial inflammation in patients with unstable angina 
pectoris, and increased expression of PTX3 has attracted 
attention as a new effect of pitavastatin.27
Pharmacokinetics of pitavastatin
Absorption, distribution, metabolism  
and excretion
In pharmacokinetic studies, pitavastatin has been demonstrated 
to show a high bioavailablity of 80% in rats and 88% in canines 
after administration at the dose of 1 mg/kg. It is distributed 
selectively to the target organ, the liver, and pharmacokinetic 
studies in rats conducted using  14C-pitavastatin have 
confirmed approximately 54 times higher radioactivity in 
the liver than that in the serum.36
Figure 3 shows the metabolic pathway of pitavastatin. 
Many lipophillic drugs are metabolized in the liver by the 
drug-metabolizing enzyme, cytochrome P450 (CYP).37,38 
Statins are also metabolized by CYPs, for example, lipophilic 
statins such as simvastatin and atorvastatin are metabolized 
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Figure 3 Metabolic pathway of pitavastatin.   Adapted with permission from Fujino H, Yamada I, Shimada S, et al. Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA 
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by CYP3A4, and fluvastatin by CYP2C9.39 Pitavastatin is 
lipophilic, but is scarcely metabolized by CYPs. It is rapidly 
glucuronized by uridine diphosphate-glucuronyltransferase 
(UGT) 1A1, UGT1A3, and UGT2B7, and is then converted 
to pitavastatin lactone, an inactive form, by elimination 
reaction of the glucuronic acid.37 Pitavastatin is minimally 
metabolized by CYP2C9 to the M-13 form,40 which is 
not detected clinically.41 The CYP metabolic properties of 
pitavastatin are similar to those of the hydrophilic pravastatin 
and rosuvastatin, and pitavastatin is classified into a non-CYP 
metabolizable type (Table 3).39 All statins but pitavastatin 
are metabolized by CYP3A4 after being transformed to the 
lactone form through glucuronidation, however, pitavastatin 
lactone is not metabolized by CYPs.38
To evaluate the effects of grapefruit juice (GFJ), a CYP3A4 
inhibitor, on the pharmacokinetics of pitavastatin and atorvas-
tatin, 8 healthy adults were administered either GFJ or water 
3 times daily for 4 days, followed by a single dose of 4 mg 
pitavastatin or 20 mg atorvastatin. GFJ increased the area under 
the curve (AUC) 0–24 of atorvastatin by 83% (95% confidence 
interval [CI] 23% to 144%) and that of pitavastatin by only 13% 
(–3% to 29%).42 Pitavastatin appears to be scarcely affected by 
CYP3A4-mediated drug–drug interaction.
The in vitro inhibitory effects of each type of statin on 
CYP metabolism were evaluated using model substrates. 
Simvastatin, simvastatin acid, and atorvastatin lactone 
inhibited CYP metabolism of the model substrates, while 
pitavastatin scarcely inhibited it.43 This result suggests that 
pitavastatin is scarcely involved in drug–drug interactions 
mediated by CYPs.
As for the distribution of pitavastatin, it is reported to 
be taken up into the liver through organic anion transporter 
protein 2 (OATP2),44 and the AUC0–24 of pitavastatin was 
increased by 4.6-fold by concurrent administration of 
cyclosporine, an OATP2 inhibitor.45 Other statins are also 
reported to be taken up into the liver, mainly by OATP2, and 
combined therapy with cyclosporine increases their plasma 
concentrations.46 On the other hand, multidrug resistance 
Table 3 Pharmacokinetic parameters of statins
Statin Pitavastatin Atorvastatin Fluvastatin Lovastatin Pravastatin Rosuvastatin Simvastatin
Molecular weight 881 1209 433.5 405 446.5 1001 418.15
Origin Synthetic Synthetic Synthetic Microbial Semi-synthetic 
(microbial origin)
Synthetic Semi-synthetic 
(microbial origin)
Racemic No No Yes No No No No
Prodrug No No No Yes No No Yes
Log P 1.49 1.11 1.27 1.70 −0.84 −0.33 1.60
Absorption (%) 80 30 98 31 37 50 65–85
Hepatic excretion (%) NA 70 68 70 66 90 78–87
Bioavailability (%) 60 12 10–35 5 17 20 5
effect of food on 
bioavailability (%)
No Yes (↓13) Yes (↓15–25) Yes (↑50) Yes (↓30) No No
Protein binding (%) 96 98 98 96–98.5 43–54 88 95
Tmax 0.5–0.8 2.0–4.0 0.5–1.5 2.8 0.9–1.6 3 1.3–2.4
T1/2 11 11–30 0.5–2.3 2.5–3.0 0.8–3.0 20 1.9–3.0
Renal excretion 2 2 6 30 60 10 13
50% inhibitory concen-
tration (nmol/L)
6.8 15.2 17.9 2.7–11.1 55.1 12 18.1
Lipid-lowering 
Metabolites
No Yes, active Yes, mainly 
inactive
Yes Yes, mainly  
inactive
No Yes
Range of dose (mg) 1–4 10–80 20–80 10–80 5–40 5–80 5–80
CYP isoforms 
primarily involving with 
metabolic pathway
CYP2C9 
Minimally
CYP3A4 CYP2C9 CYP3A4 CYP3A4 Minimally CYP2C9 
Minimally
CYP3A4
Notes: Log P, logarithm of base 10 of the n-octanol/water partition coefficient of active hydroxy forms of statins.
Abbreviation: CYP, cytochrome P450.
Modified from Fujino et al.37Vascular Health and Risk Management 2009:5 927
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protein 1 (MDR1), a P glycoprotein, is not involved in 
pitavastatin pharmacokinetics.47
Combined therapy may cause an increase in the blood 
concentration of either drug to increase the incidence of 
adverse drug reactions and enhance the effects. Pitavastatin 
is non-CYP metabolizable and rarely causes drug–drug 
interactions through CYP isoforms. Therefore, pitavastatin 
is expected to be easily applied for the treatment of patients 
with metabolic syndrome, which may require multidrug 
therapy, including drugs for dyslipidemia, hypertension and 
diabetes.
Pharmacokinetic study in patients  
with liver dysfunction
After administration of a single 2 mg dose pitavastatin, the 
plasma concentrations of 12 male patients with liver cirrhosis 
(6 patients with Child–Pugh grade A, 6 with Child–Pugh 
grade B disease) were compared with those of 6 healthy 
male volunteers without liver disease. 1.19- and 2.47-fold 
increase of the Cmax, and 1.27- and 3.64-fold increase of 
the AUCt were observed in patients with Child–Pugh grade 
A and Child–Pugh grade B, respectively, as compared with 
the values in healthy adults without liver disease.48
Pharmacokinetic study in the elderly
The  pharmacokinetics  of  plasma  pitavastatin  and 
pitavastatin lactone were compared between 6 elderly 
subjects aged 65 to 71 years and 5 non-elderly subjects aged 
22 to 24 years who received repeated oral administration of 
pitavastatin 2 mg for 5 days. Pharmacokinetic parameters 
of pitavastatin and pitavastatin lactone did not significantly 
differ between the elderly and the non-elderly. Aging is 
considered to cause little change in the pharmacokinetics 
of pitavastatin.49
Studies on efficacy
Studies of the LDL-C-lowering effect  
of pitavastatin
The LDL-C-lowering effect of statins increases in a dose-
dependent manner, and the safety risk increases with dose 
escalation.50 Therefore, the LDL-C-lowering effect at the 
initial dose is important, and the statins are classified into 
strong statins, which have a strong LDL-C-lowering action 
at the initial doses, including atorvastatin and rosuvastatin, 
and others.51 Pitavastatin belongs to the category of strong 
statins due to the similar LDL-C-lowering action of this drug 
to that of atorvastatin at the initial dose.
In a dose-finding study in patients with hypercholesterolemia 
conducted in Japan, where pitavastatin was first developed, 
the LDL-C-lowering effect of pitavastatin after 12-week 
administration was 34% (n = 81) at the dose of 1 mg, 42% 
(n = 75) at the dose of 2 mg, and 47% (n = 76) at the dose of 
4 mg.52 In a Phase III study, the effect of 12-week treatment 
with pitavastatin 2 mg was compared with that of pravastatin 
10 mg. The mean percent reduction in LDL-C following 
pitavastatin treatment was 38% (n = 120) and that following 
pravastatin treatment was 18% (n = 105).53 LDL-C reduction 
by pitavastatin 4 mg was observed by 46% (n = 25) after 
8-week administration in another Phase II study similar to the 
dose finding study.54 Almost similar results were obtained in 
the development studies conducted in Korea and Europe. In a 
Phase III study conducted in Korea, mean percent reduction 
in LDL-C after 8-week administration of pitavastatin 2 mg 
(n = 49) was 38%, similar to that in the control simvastatin 
20 mg group (n = 46).55 In a Phase III study conducted in 
Europe, mean percent reduction in LDL-C following 12-week 
administration of pitavastatin 2 mg (n = 315) and 4 mg 
(n = 298) were 38% and 45%, respectively, being comparable 
to that observed following administration of the control 
drug atorvastatin at 10 mg (n = 102) and 20 mg (n = 102) 
(Figure 4).56 In another Phase III study in Europe compared 
pitavastatin and simvastatin with the same design, pitavastatin 
2 mg demonstrated significantly superior reduction in LDL-C 
by 39% (n = 307) to that of simvastatin 20 mg by 35% 
(n = 107) (p = 0.014) while pitavastatin 4 mg and simvastatin 
40 mg demonstrated similar reduction in LDL-C by 44% 
(n = 319) and 43% (n = 110), respectively.57
The efficacy of pitavastatin was evaluated in 30 hetero-
zygous familial hypercholesterolemia patients. Decrease of 
the serum LDL-C levels by 40% was observed after 8-week 
administration of pitavastatin 2 mg, and by 48% after another 
8-week administration at the dose of 4 mg.58
From the above-mentioned clinical results on the 
LDL-C-lowering efficacy of statins, the LDL-C-lowering 
action of pitavastatin at doses of 2 to 4 mg was as strong 
as that of atorvastatin at doses of 10 to 20 mg; also, 
pitavastatin 2 mg was efficacious equivalent or more than 
simvastatin 20 mg.
Studies of the efficacy of pitavastatin  
on lipid parameters other than LDL-C
Since even in patients with sufficiently reduced serum LDL-C 
levels, development of atherosclerotic disease, especially 
CHD, is not fully prevented, other risk factors than LDL-C 
also should be considered. The clinical effects of pitavastatin Vascular Health and Risk Management 2009:5 928
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on various lipid parameters other than LDL-C have been 
reported. In particular, pitavastatin has been demonstrated 
to show superior HDL-C-elevating effect as compared to 
atorvastatin.
In a Phase III study conducted in Japan, administration of 
pitavastatin 2 mg produced a statistically significant increase 
of the serum HDL-C level by 8.9%.54 In a Phase III study 
conducted in Europe, significant increases of the serum 
HDL-C level by 4.0% and 5.0% were observed following 
administration of pitavastatin at the doses of 2 mg and 4 mg, 
respectively. In the same study, increases of the serum HDL-C 
level by 3.0% and 2.5% were observed following admin-
istration of atorvastatin at the doses of 10 mg and 20 mg, 
respectively, there being no significant difference in effect 
from that of pitavastatin.56
The HDL-C-elevating effect of some statins has been 
reported to diminish with long-term treatment.59 A phase 
III long-term administration study of pitavastatin 1 to 4 mg 
for 52 weeks was conducted in 317 patients. The serum 
HDL-C level, which was 56.0 ± 15.7 mg/dL at the baseline, 
showed significant and sustained increase from 4 weeks of 
treatment, to rise by 6.0 mg/dL after 52 weeks (Figure 5).60 
A total of 43 hypercholesterolemic patients with low serum 
HDL-C levels were examined to determine the effect of 
pitavastatin on the serum HDL-C levels. Administration of 
pitavastatin produced a significant and sustained increase 
of the serum HDL-C levels (from 36.0 ± 5.9 mg/dL at base-
line to 40.5 ± 9.1 mg/dL at 12 months, P  0.001) and Apo 
A-I levels (from 108.4 ± 18.0 mg/dL to 118.7 ± 19.3 mg/dL, 
P  0.01).61 In a clinical study conducted to confirm the 
effect of pitavastatin on the HDL metabolism,30 29 patients 
with hypercholesterolemia were treated with pitavastatin 
2 mg for 4 weeks. In this study, pitavastatin administration 
produced a decrease of the serum total cholesterol by 
26.9% and of the serum LDL-C levels by 39.8%, with 
increase of the serum HDL-C and HDL2-C levels by 6.0% 
and 9.0%, respectively. On the other hand, there was no 
change of the serum HDL3-C level and significant decrease 
of the serum preβ1-HDL level.62 In a randomized study 
comparing the HDL-C-elevating effect of pitavastatin 2 mg 
with that of atorvastatin 10 mg for 52 weeks, pitavastatin 
(n = 88) was significantly superior to atorvastatin (n = 85) 
in increasing the serum HDL-C levels (8.2% vs 2.9%, 
P = 0.031). The percent change in the serum Apo A-1 level 
in the pitavastatin group was significantly higher (5.1%) 
than that in the atorvastatin group (0.6%) (P = 0.019).63 
In a comparative study of pitavastatin and atorvastatin 
in Japanese hypercholesterolemic patients (Collabora-
tive Study on Hypercholesterolemia Drug Intervention 
and Their Benefits for Atherosclerosis Prevention 
Pitavastatin favor Atorvastatin favor
Atorvastatin 10 mg – Pitavastatin 2 mg 
Atorvastatin 20 mg – Pitavastatin 4 mg 
Difference of LDL-C reduction of atorvastatin from pitavastatin
−8 −6 −4 −2 0 2 4 6 8
Figure 4 95% confidence interval on treatment difference in adjusted mean percentage change in LDL-C observed in phase III double-blind clinical trial of pitavastatin vs 
atorvastatin.56
Note: Non-inferiority margin of LDL-C reduction by pitavastatin to that by atorvastatin was set to –6%.Vascular Health and Risk Management 2009:5 929
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[CHIBA study]), the efficacy of pitavastatin 2 mg on 
the serum non-HDL-C levels was compared with that of 
atorvastatin 10 mg after 12-week treatment. The results 
revealed similar reduction of the serum non-HDL-C levels 
with pitavastatin treatment (39.0%, n = 93) and atorvastatin 
treatment (40.3%, n = 98), but a significant increase of the 
serum HDL-C levels only with pitavastatin treatment. In the 
CHIBA study, the waist circumference, body weight, and 
body mass index (BMI) were correlated with the percent 
reduction of the serum non-HDL-C only in the atorvastatin 
group. Improvement of the lipid parameters in the subgroup 
of patients with metabolic syndrome was more favorable 
in the pitavastatin group (n = 28) than in the atorvastatin 
group (n = 25). The pitavastatin group showed a significant 
increase of the serum HDL-C levels and decrease of the 
serum TG levels.64
As for the TG-lowering effect of pitavastatin in patients 
with pretreatment TG levels of 150 mg/dL or more, in a 
phase III study, pitavastatin 2 mg administration for 12 weeks 
(n = 50) produced a significant decrease of the serum TG 
levels by 23%, and in a phase II study, treatment with 4 mg of 
the drug for 8 weeks (n = 25) produced a significant decrease 
of the serum TG levels by 42%.52,54 In a double-blind placebo 
controlled cross-over study, pitavastatin 2 mg produced a 
significant decrease of the serum TG levels by 20% compared 
with placebo.65
The effects of pitavastatin on the serum levels of other 
atherogenic lipoproteins, including remnant-like particle 
cholesterol (RLP-C) and small, dense LDL, have also been 
investigated. A total of 34 hypercholesterolemic patients 
with type 2 diabetes were treated with pitavastatin 2 mg for 
8 weeks. With the treatment, significant decrease of the serum 
RLP-C levels and the proportion of small, dense LDL, and 
significant increase of the peak particle diameter, an indica-
tor of the LDL particle size, were observed.66 In the Kansai 
Investigation of Statin for Hyperlipidemic Intervention in 
Metabolism and Endocrinology (KISHIMEN), pitavastatin 
at the dose of 1 or 2 mg was administered to 178 patients 
with hypercholesterolemia for 6 to 12 months. Significant 
decreases of the serum LDL-C and RLP-C levels by 30.3% 
(n = 139) and 22.8% (n = 47), respectively, were observed. 
Serum TG levels decreased by 15.9% in 64 patients with 
basal TG levels of 150 mg/dL or more, and the serum HDL-C 
levels significantly increased.67 The effects of pitavastatin 2 
mg on the serum RLP-C and small, dense LDL-cholesterol 
levels were compared with those of atorvastatin 10 mg in 
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Figure 5 Time course of mean HDL-C over 52 weeks in a long-term study of pitavastatin.60
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heterozygous patients with familial hypercholesterolemia. 
A total of 17 heterozygous patients with familial hypercho-
lesterolemia received pitavastatin 2 mg or atorvastatin 10 mg. 
After 12 weeks, the serum levels of RLP-C and small, dense 
LDL-C were significantly reduced in both groups, with no 
differences noted between the groups.68
From the above clinical results on the effects of pitavas-
tatin on lipid parameters other than LDL-C, pitavastatin 
exhibits TG-reducing and HDL-C-elevating effects, and the 
HDL-C elevating effect of pitavastatin is superior to that of 
atorvastatin. Pitavastatin also improves other atherogenic 
lipid parameters, including non-HDL-C, small, dense LDL, 
and RLP-C, as efficiently as atorvastatin. These comprehen-
sive effects of pitavastatin on the lipid profile is expected to 
exert favorable effects on abnormal atherogenic lipoproteins 
and dysfunction of anti-atherosclerotic lipoproteins, which 
are typically noted in patients with metabolic syndrome, who 
need sufficient LDL-C-lowering treatment for reducing the 
risk of CHD, and frequently have hypertriglyceridemia and 
hypo-HDL-cholesterolemia.
Studies of the efficacy of pitavastatin on 
factors other than the lipid parameters
Since pitavastatin 2 to 4 mg has been demonstrated to show 
potent LDL-C reducing effects equivalent to atorvastatin 
10 to 20 mg, it was expected that this drug would also reduce 
the risk of cardiovascular events, like atorvastatin. Several 
clinical studies have consistently demonstrated the efficacy 
of pitavastatin on plaques in the coronary arteries and in 
the carotid arteries while the usefulness of this effect as a 
surrogate marker is controversial.
Eighty-two patients matched for age and gender from 
among 870 patients undergoing intravascular ultrasound 
(IVUS)-guided percutaneous coronary intervention (PCI) 
were retrospectively assigned to either lipid-lowering therapy 
(n = 41, pitavastatin 2 mg) or a control group (n = 41, 
diet only). Significant reduction of the plaque volume index 
(PVI) was observed in the pitavastatin group (10.6% ± 9.4% 
decrease) as compared with that in the control group 
(8.1% ± 14.0% increase, P  0.001). There were significant 
correlations between the percent change in the PVI and 
the follow-up serum LDL-C levels (r = 0.500, P  0.001) 
and percent change of the serum LDL-C levels (r = 0.479, 
P  0.001).69 A prospective study to determine the effects on 
carotid plaques was conducted in patients treated with pitavas-
tatin 4 mg (n = 33) or placebo (n = 32) within 3 days of onset 
of the acute coronary syndrome (ACS). In the pitavastatin 
group, greater improvement of the vulnerable carotid plaques 
at 1 month, as analyzed by carotid ultrasound integrated 
backscatter (IBS), was observed in the pitavastatin group as 
compared with that in the placebo group. Significantly greater 
improvement of the levels of inflammatory biomarkers, such 
as C-reactive protein (CRP), vascular endotherial growth 
factor (VEGF), and tumor necrosis factor alpha (TNF-α), 
at 1 month was observed in the pitavastatin group as compared 
with that in the placebo group.70 To evaluate the effect on 
coronary plaques prospectively, the Japan Assessment of 
Pitavastatin and Atorvastatin in Acute Coronary Syndrome 
(JAPAN-ACS) Study was conducted in 252 patients with ACS 
who underwent IVUS-guided PCI. The effects of 8-month 
treatment with pitavastatin 4 mg and atorvastatin 20 mg 
were compared. The mean percent change in the plaque 
volume (PV) was –16.9% ± 13.9% in the pitavastain group 
and –18.1% ± 14.2% in the atorvastatin group, indicating 
a significant decrease in both groups. Administration of 
pitavastatin in patients with ACS is thus supposed to cause 
regression of coronary plaques (Table 4).71 A similar study 
using pravastatin as control is ongoing.72
In addition, administration of pitavastatin has been 
reported to induce a decrease in the serum level of 
high-sensitivity CRP associated with atherosclerosis, and 
increase in the serum level of adiponectin.67,73 The short- and 
intermediate-term effects of pitavastatin and atorvastatin on 
the endothelial functions have been evaluated. The short-term 
Table 4 Percent changes of parameters for coronary plaque observed in JAPAN-ACS study
Both groups 
(n = 252)
P value  
compared 
with baseline
Pitavastatin 
(n = 125)
P value  
compared with 
baseline
Atorvastatin 
(n = 127)
P value  
compared 
with baseline
P value 
between 
groups
Plaque volume (mm3) −17.5 ± 14.0 0.001 −16.9 ± 13.9 0.001 −18.1 ± 14.2 0.001 0.5
Vessel volume (mm3) −6.0 ± 11.4 0.001 −5.9 ± 11.8 0.001 −6.2 ± 11.1 0.001 0.8
Lumen volume (mm3) 6.5 ± 20.4 0.001 6.4 ± 21.5 0.0012 6.6 ± 19.4 0.001 0.9
Adapted with permission from Hiro T, Kimura T, Morimoto T, et al. effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute 
coronary syndrome: a multi-center randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS Study). J Am Coll 
Cardiol. 2009;54:293–302.71 Copyright © 2009 elsevier.Vascular Health and Risk Management 2009:5 931
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effects of pitavastatin on the endothelial functions were 
superior to those of atorvastatin.74 Moreover, beneficial 
effects of pitavastatin on the cardiac and renal functions, 
as well as on bone metabolism, have been reported.75–77 
A clinical study is ongoing to evaluate the effect of pitavas-
tatin for prevention of type 2 diabetes mellitus.78
Safety and tolerability
According to the clinical findings obtained to date, the safety 
of pitavastatin at the initial dose is equivalent to that of the 
statins already on the market, and the tolerability at the 
initial dose is equivalent to that of atorvastatin. Pitavastatin 
is supposed to rarely cause adverse drug reactions (ADRs) 
related to glucose metabolism and the kidneys, notable new 
ADRs of strong statins.
integrated safety analysis  
of clinical studies
In the clinical studies conducted in Japan prior to the drug 
approval, ADRs, as defined by signs and symptoms, occurred 
in 50 (5.6%) out of 886 patients. ADRs, as defined by 
laboratory abnormalities, occurred in 167 patients (18.8%), 
and included increase of the serum γ-glutamyl-transferase 
(GTP), creatine phosphokinase (CK [CPK]), serum alanine 
aminotransferase (ALT [glutamic pyruvic transaminase, 
GPT]), and aspartate aminotransferase (AST [glutamic 
oxaloacetic transaminase, GOT]) values, not specific to 
pitavastatin, and their frequency and severity were similar to 
those noted for the existing statins.51 The incidence of ADRs 
by the dose of pitavastatin, as defined by signs, symptoms 
and laboratory abnormalities, for each dose was 20.3% 
(26/128 patients) for 1 mg, 23.3% (121/519) for 2 mg, and 
20.9% (50/239) for 4 mg, demonstrating the absence of a 
dose relationship. There was no increase in the incidence or 
severity of ADRs due to long-term administration, and no 
development of new ADRs.79
Comparative studies with other statins
In the Phase III double-blind comparative studies conducted 
in Japan, Korea and Europe, the safety profile of pitavastatin 
2 mg was similar to that of pravastatin 10 mg, simvastatin 20 
mg, and atorvastatin 10 mg. Thus, the safety of pitavastatin 
at the initial dose is considered to be equivalent to that of the 
other existing statins. Pitavastatin showed similar tolerability 
to atorvastatin 10 mg, and the safety of pitavastatin at an initial 
dose appeared to be same as that of atorvastatin.53,55,56
ADRs due to high-dose statins are reported to be associated 
with a decrease in coenzyme Q10 (CoQ10). An open, 
randomized, cross-over study using pitavastatin 4 mg and 
atorvastatin 20 mg was conducted to compare their efficacy, 
safety, and effect to decrease the CoQ10 levels at an increased 
dose of them in 19 Japanese patients with heterozygous familial 
hypercholesterolemia. Plasma levels of CoQ10 were reduced 
by atorvastatin (–26.1%, P = 0.0007), but not by pitavastatin 
(–7.7%, P = 0.39).80
effects on glucose metabolism
Several studies have reported deterioration of the glucose 
metabolism following administration of statins.81–84 The 
effects of pitavastatin on glucose metabolism have been 
reported by several clinical studies.
Pitavastatin 1 mg or 2 mg was administered for 8 weeks 
to 79 type 2 diabetic patients with hypercholesterolemia 
who had never been treated with statins, and the effects on 
the fasting plasma glucose, hemoglobin A1c (HbA1c), AST, 
ALT, γ-GTP, and CK levels were evaluated. No statistically 
significant changes in the fasting plasma glucose levels (from 
8.2 ± 2.7 to 8.3 ± 2.1 mmol/L) or HbA1c levels (from 7.3% ± 
1.6% to 7.3% ± 1.5%) were observed following administra-
tion of pitavastatin. Changes in other clinical laboratories 
were also not statistically significant. None of the subjects 
withdrew from the study because of ADRs.85
Glycemic control was retrospectively evaluated in type 
2 diabetic patients receiving atorvastatin 10 mg (n = 99), 
pravastatin 10 mg (n = 85), or pitavastatin 2 mg (n = 95) 
for 3 months. The random blood glucose and HbA1c levels 
deteriorated only in the atorvastatin group.86
A basic research was conducted to examine glucose 
uptake by insulin under administration of atorvastatin, 
simvastatin, pravastatin, or pitavastatin using 3T3-L1 
cells. Glucose uptake was reduced in the atorvastatin and 
simvastatin groups, while no change was observed in the 
pravastatin or pitavastatin group. Reduction of solute carrier 
family 2, member 4 (SLC2A4) and CCAAT/enhancer binding 
protein (C/EBP) α expressions, involved in glucose uptake by 
cells, may occur, leading to a decrease of the glucose uptake 
following administration of atorvastatin.87
Patient-focused outcomes
To detect 99% or more of unknown ADRs with an incidence 
of 0.05% or more, the LIVALO Effectiveness and Safety 
(LIVES) study was conducted in about 20000 patients with 
hypercholesterolemia or familial hypercholesterolemia for 
up to 2 years. A total of 20,279 patients were enrolled from 
2811 facilities. The Treatment Outcome Study reported the 
analyzed results for 3 months after the initiation of pitavastatin Vascular Health and Risk Management 2009:5 932
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administration. According to the results of 3-month treatment, 
the incidence of ADRs was 6.1% (1206/19921 patients).88 
As for the treatment outcome studies of other strong statins, 
the incidence of ADRs was 12.0% (576/4805 patients) for 
Lipitor® (atorvastatin) and 11.1% (978/8795 patients) for 
Crestor® (rosvastatin). The incidence of ADRs to pitavastatin 
was about a half compared with the above incidences.89,90
According to the analyzed results after 2 years of 
pitavastatin administration, the incidence of ADRs was 
10.4%. Regarding the main ADRs of statins, the incidence of 
ADRs related to the musculoskeletal system was 2.1%, and 
that related to liver dysfunction was 1.0%. According to the 
severity, mild ADRs occurred in 1045 patients, moderate in 
155, and severe in 6 patients. Almost all of the ADRs were 
classified as mild. Table 2 shows the major ADRs. The major 
ADRs, CK increased and transaminase increased, occurred 
less frequently than that noted with other strong statins. The 
ADRs related to glucose metabolism or the kidneys, notable 
new ADRs of strong statins, scarcely occurred. In the strati-
fied analysis on the occurrence of ADRs by the concomitantly 
administered drugs, no significant increase in the incidence of 
ADRs was observed even when azole antifungals, macrolide 
antibiotics, or coumarin anticoagulants, which should be given 
with care due to drug–drug interactions though CYPs for 
other statins, were administered concomitantly. In addition, 
concomitant administration of various antiplatelet, antihyper-
tensive and/or antidiabetic drugs did not significantly increase 
the incidence of ADRs. These results suggest the absence of 
any special problems related to drug-drug interactions for 
pitavastatin. Figure 6 shows the presumed cumulative inci-
dence of ADRs using the Kaplan-Meier method over 2 years 
after the initiation of pitavastatin treatment. The incidence 
rose gradually from 12 weeks to 52 weeks, with no abrupt 
increase in the incidence of ADRs.91
The results at 104 weeks have been analyzed until date, 
and the LIVES-Extension study is ongoing; it is expected 
to be carried out for another 3 years, with total follow-up 
duration of 5 years.
Conclusion
Cerivastatin was withdrawn from the market due to reports of fatal 
rhabdomyolysis induced by high-doses of cerivastatin or drug–
drug interactions caused by coadministration of gemfibrozil. 
Recently, strong statins such as atorvastatin and rosuvastatin 
have been widely used for their potent LDL-C-lowering 
effect at the initial dose, and combinations of these drugs with 
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ezetimibe have been more frequently applied than increase in 
the dose of the statins. However, serum LDL-C treatment goal 
have not been achieved in high-risk patients, particularly those 
with multiple risk factors for CHD in routine clinical settings 
in Europe, the US, or Japan. Therefore, since high-dose statin 
administration should be avoided, it is anticipated that a new 
drug to be coadministered with statins will appear as an alter-
native to ezemitibe in the future.
Pitavastatin is a strong statin with the same LDL-C-
lowering effect as that of atorvastatin at the initial dose and 
associated with minimal drug–drug interactions. Although 
various LDL-C-lowering drugs under development are 
expected to become available for clinical use in the future, 
the use of statins as the mainstay for the treatment of dyslip-
idemias appears to remain unchanged. Therefore, pitavastatin 
may have the potential to become the standard drug for 
dyslipidemia treatment because of its potent LDL-C-lowering 
effect, equivalent to that of atorvastatin at the initial dose, 
and association with minimal drug–drug interactions.
Moreover, pitavastatin has TG-lowering and HDL-elevating 
effects, and is anticipated to be useful in improving the 
overall lipid profile. In particular, serum HDL-C elevation 
by pitavastatin is superior to that observed for atorvastatin. 
These pitavastatin profiles are favorable for the treatment of 
metabolic syndrome patients, which is a major concern in 
developed countries because of its association with a high 
risk of CHD. The reasons why pitavastatin would be favored 
for the treatment of metabolic syndrome are as follows. First, 
the serum LDL-C levels are not markedly elevated in most 
patients with metabolic syndrome, however, these patients 
also require sufficient decrease of the serum LDL-C because 
of the associated high risk of CHD. Second, patients with 
metabolic syndrome frequently show elevated serum TG and 
reduced serum HDL-C levels, and statin monotherapy is often 
inadequate for satisfactory overall control of the lipid profile. 
Since pitavastatin is a strong statin associated with a low 
risk of drug–drug interactions, there is little concern about 
drug–drug interactions when it is administered to patients 
with metabolic syndrome in combination with antihyper-
tensive and/or antidiabetic agents. Therefore, pitavastatin 
may have the potential to become the standard drug for the 
treatment of metabolic syndrome, because it is suitable for 
improving the overall lipid profile in patients with metabolic 
syndrome, the incidence of which appears to continue to 
increase throughout the world, and the drug is associated 
with a low risk of drug–drug interactions.
In conclusion, pitavastatin is strongly expected to become 
a standard agent for the treatment of dyslipidemia, especially 
for the treatment of dyslipidemia in patients with metabolic 
syndrome.
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